1
|
Wang Z, Li H, Gou L, Li W, Wang Y. Antibody-drug conjugates: Recent advances in payloads. Acta Pharm Sin B 2023; 13:4025-4059. [PMID: 37799390 PMCID: PMC10547921 DOI: 10.1016/j.apsb.2023.06.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 04/30/2023] [Accepted: 06/23/2023] [Indexed: 10/05/2023] Open
Abstract
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads with efficient killing, show great clinical therapeutic value. The ADCs' payloads play a key role in determining the efficacy of ADC drugs and thus have attracted great attention in the field. An ideal ADC payload should possess sufficient toxicity, low immunogenicity, high stability, and modifiable functional groups. Common ADC payloads include tubulin inhibitors and DNA damaging agents, with tubulin inhibitors accounting for more than half of the ADC drugs in clinical development. However, due to clinical limitations of traditional ADC payloads, such as inadequate efficacy and the development of acquired drug resistance, novel highly efficient payloads with diverse targets and reduced side effects are being developed. This perspective summarizes the recent research advances of traditional and novel ADC payloads with main focuses on the structure-activity relationship studies, co-crystal structures, and designing strategies, and further discusses the future research directions of ADC payloads. This review also aims to provide valuable references and future directions for the development of novel ADC payloads that will have high efficacy, low toxicity, adequate stability, and abilities to overcome drug resistance.
Collapse
Affiliation(s)
- Zhijia Wang
- Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy, Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu 610041, China
- Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu 610212, China
| | - Hanxuan Li
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA
| | - Lantu Gou
- Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy, Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Wei Li
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA
| | - Yuxi Wang
- Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy, Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu 610041, China
- Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu 610212, China
| |
Collapse
|
2
|
Tran AT, Tran CV, Le HV, Tran LV, Tran TTP, Tran SV. Design, Synthesis, and Cytotoxic Activity of New Tubulysin Analogues. Synlett 2021. [DOI: 10.1055/s-0041-1737139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
AbstractSynthesis of tubulysin analogues, containing an N-methyl substituent on tubuvaline-amide together with the replacement of either the hydrophobic N-terminal N-methyl pipecolic acid (Mep) or at both N- and C- terminal peptides with available heteroaromatic acids and an unsaturated tubuphenylalanine moiety, respectively, were described. The in vitro cytotoxic activity by SRB assay on five cancer cell lines for sixteen tubulysins was evaluated. Among them, five analogues exhibited strong cytotoxic activities against five human cancer cell lines, including human breast carcinoma (MCF7), human colorectal adenocarcinoma (HT-29), HL-60, SW-480, human lung adenocarcinoma (A459). Interestingly, one analogue showed the strongest cytotoxicity on all five tested cell lines even much higher toxicity than the reference compound ellipticine.
Collapse
Affiliation(s)
- Anh Tuan Tran
- University of Science and Technology of Hanoi, Vietnam Academy of Science and Technology
| | - Chien Van Tran
- Institute of Chemistry, Vietnam Academy of Science and Technology
- Graduate University of Science and Technology, Vietnam Academy of Science and Technology
| | - Hai Van Le
- Institute of Chemistry, Vietnam Academy of Science and Technology
- Graduate University of Science and Technology, Vietnam Academy of Science and Technology
| | - Loc Van Tran
- Institute of Chemistry, Vietnam Academy of Science and Technology
- Graduate University of Science and Technology, Vietnam Academy of Science and Technology
| | - Thao Thi Phuong Tran
- Institute of Chemistry, Vietnam Academy of Science and Technology
- Graduate University of Science and Technology, Vietnam Academy of Science and Technology
| | - Sung Van Tran
- Institute of Chemistry, Vietnam Academy of Science and Technology
| |
Collapse
|
4
|
Nicolaou KC, Pan S, Pulukuri KK, Ye Q, Rigol S, Erande RD, Vourloumis D, Nocek BP, Munneke S, Lyssikatos J, Valdiosera A, Gu C, Lin B, Sarvaiaya H, Trinidad J, Sandoval J, Lee C, Hammond M, Aujay M, Taylor N, Pysz M, Purcell JW, Gavrilyuk J. Design, Synthesis, and Biological Evaluation of Tubulysin Analogues, Linker-Drugs, and Antibody-Drug Conjugates, Insights into Structure-Activity Relationships, and Tubulysin-Tubulin Binding Derived from X-ray Crystallographic Analysis. J Org Chem 2021; 86:3377-3421. [PMID: 33544599 DOI: 10.1021/acs.joc.0c02755] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Molecular design, synthesis, and biological evaluation of tubulysin analogues, linker-drugs, and antibody-drug conjugates are described. Among the new discoveries reported is the identification of new potent analogues within the tubulysin family that carry a C11 alkyl ether substituent, rather than the usual ester structural motif at that position, a fact that endows the former with higher plasma stability than that of the latter. Also described herein are X-ray crystallographic analysis studies of two tubulin-tubulysin complexes formed within the α/β interface between two tubulin heterodimers and two highly potent tubulysin analogues, one of which exhibited a different binding mode to the one previously reported for tubulysin M. The X-ray crystallographic analysis-derived new insights into the binding modes of these tubulysin analogues explain their potencies and provide inspiration for further design, synthesis, and biological investigations within this class of antitumor agents. A number of these analogues were conjugated as payloads with appropriate linkers at different sites allowing their attachment onto targeting antibodies for cancer therapies. A number of such antibody-drug conjugates were constructed and tested, both in vivo and in vitro, leading to the identification of at least one promising ADC (Herceptin-LD3), warranting further investigations.
Collapse
Affiliation(s)
- K C Nicolaou
- Department of Chemistry, BioScience Research Collaborative, Rice University, 6100 Main Street, Houston, Texas 77005, United States
| | - Saiyong Pan
- Department of Chemistry, BioScience Research Collaborative, Rice University, 6100 Main Street, Houston, Texas 77005, United States
| | - Kiran K Pulukuri
- Department of Chemistry, BioScience Research Collaborative, Rice University, 6100 Main Street, Houston, Texas 77005, United States
| | - Qiuji Ye
- Department of Chemistry, BioScience Research Collaborative, Rice University, 6100 Main Street, Houston, Texas 77005, United States
| | - Stephan Rigol
- Department of Chemistry, BioScience Research Collaborative, Rice University, 6100 Main Street, Houston, Texas 77005, United States
| | - Rohan D Erande
- Department of Chemistry, BioScience Research Collaborative, Rice University, 6100 Main Street, Houston, Texas 77005, United States
| | - Dionisios Vourloumis
- Department of Chemistry, BioScience Research Collaborative, Rice University, 6100 Main Street, Houston, Texas 77005, United States.,Laboratory of Chemical Biology of Natural Products & Designed Molecules, Institute of Nanoscience and Nanotechnology, National Centre for Scientific Research "Demokritos", Agia Paraskevi 153 10, Greece
| | - Bogusław P Nocek
- AbbVie Inc., Research & Development, 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Stefan Munneke
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Joseph Lyssikatos
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Amanda Valdiosera
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Christine Gu
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Baiwei Lin
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Hetal Sarvaiaya
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Jose Trinidad
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Joseph Sandoval
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Christina Lee
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Mikhail Hammond
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Monette Aujay
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Nicole Taylor
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Marybeth Pysz
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - James W Purcell
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Julia Gavrilyuk
- AbbVie Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| |
Collapse
|
8
|
Nicolaou KC, Erande RD, Yin J, Vourloumis D, Aujay M, Sandoval J, Munneke S, Gavrilyuk J. Improved Total Synthesis of Tubulysins and Design, Synthesis, and Biological Evaluation of New Tubulysins with Highly Potent Cytotoxicities against Cancer Cells as Potential Payloads for Antibody-Drug Conjugates. J Am Chem Soc 2018; 140:3690-3711. [PMID: 29381062 DOI: 10.1021/jacs.7b12692] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Improved, streamlined total syntheses of natural tubulysins such as V (Tb45) and U (Tb46) and pretubulysin D (PTb-D43), and their application to the synthesis of designed tubulysin analogues (Tb44, PTb-D42, PTb-D47-PTb-D49, and Tb50-Tb120), are described. Cytotoxicity evaluation of the synthesized compounds against certain cancer cell lines revealed a number of novel analogues with exceptional potencies [e.g., Tb111: IC50 = 40 pM against MES SA (uterine sarcoma) cell line; IC50 = 6 pM against HEK 293T (human embryonic kidney cancer) cell line; and IC50 = 1.54 nM against MES SA DX (MES SA with marked multidrug resistance) cell line]. These studies led to a set of valuable structure-activity relationships that provide guidance to further molecular design, synthesis, and biological evaluation studies. The extremely potent cytotoxic compounds discovered in these investigations are highly desirable as potential payloads for antibody-drug conjugates and other drug delivery systems for personalized targeted cancer chemotherapies.
Collapse
Affiliation(s)
- K C Nicolaou
- Department of Chemistry, BioScience Research Collaborative , Rice University , 6100 Main Street , Houston , Texas 77005 , United States
| | - Rohan D Erande
- Department of Chemistry, BioScience Research Collaborative , Rice University , 6100 Main Street , Houston , Texas 77005 , United States
| | - Jun Yin
- Department of Chemistry, BioScience Research Collaborative , Rice University , 6100 Main Street , Houston , Texas 77005 , United States
| | - Dionisios Vourloumis
- Department of Chemistry, BioScience Research Collaborative , Rice University , 6100 Main Street , Houston , Texas 77005 , United States.,Laboratory of Chemical Biology of Natural Products & Designed Molecules , N.C.S.R "Demokritos" , 153 10 Agia Paraskevi , Athens , Greece
| | - Monette Aujay
- AbbVie Stemcentrx, LLC , 450 East Jamie Court , South San Francisco , California 94080 , United States
| | - Joseph Sandoval
- AbbVie Stemcentrx, LLC , 450 East Jamie Court , South San Francisco , California 94080 , United States
| | - Stefan Munneke
- AbbVie Stemcentrx, LLC , 450 East Jamie Court , South San Francisco , California 94080 , United States
| | - Julia Gavrilyuk
- AbbVie Stemcentrx, LLC , 450 East Jamie Court , South San Francisco , California 94080 , United States
| |
Collapse
|